Capvaxive
Q2 2026 sales $184M, up 42%; FDA label extended to children aged 2 to 17 at increased risk.
The numbers
Sales$184MQ2 2026 · +42% reported, +40% ex-FX · source ↗
What it is
Pneumococcal conjugate vaccine for adults, for adults.
Why it matters to the stock. Capvaxive is Merck's main entry into adult pneumonia prevention, a market where share gains are slow to show up in sales.
News
FDA extends Capvaxive to children and adolescents aged 2 to 17 at increased risk of pneumococcal disease
The FDA approved an expanded Capvaxive indication for children and adolescents aged 2 through 17 who have finished a primary pediatric pneumococcal series and have at least one chronic medical condition that raises their risk.
Regulation